Karim Abul B M F, Afra Denes, Cornu Philippe, Bleehan Norman, Schraub Simon, De Witte Olivier, Darcel François, Stenning Sally, Pierart Marianne, Van Glabbeke Martine
Department of Radiation Oncology, Vrije University Hospital, Amsterdam, The Netherlands.
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24. doi: 10.1016/s0360-3016(01)02692-x.
There is no consensus on the treatment strategy for adult patients with cerebral low-grade glioma. The diagnosis and primary treatment are usually undertaken by surgery. Some investigators doubt the efficacy of postoperative radiotherapy (RT), whereas others advise routine postoperative RT. We report the primary results of a multicenter randomized trial on this controversy.
From 24 European centers, 311 adult patients with low-grade glioma were randomized centrally after surgery from March 1986 through September 1997, between the two arms of the trial. The irradiated group received 54 Gy in 6 weeks. The other patients did not receive any treatment after surgery until the tumor showed progression, defined as clinical-neurologic deterioration and evidence of progressive tumor on imaging.
Of 290 eligible and assessable patients (93%), the irradiated group showed a significant (log-rank p = 0.02) improvement in time to progression but not in overall survival, with a median follow-up of 5 years. The 5-year estimate was, respectively, 63% vs. 66% (overall survival) and 44% vs. 37% (time to progression) for the treated and control arms. Different treatment modalities, including RT, were undertaken for the 85 controls when a progressive tumor was noted.
Early postoperative conventional RT such as that used for this protocol appears to improve the time to progression or progression-free survival, but not overall survival, for patients with low-grade glioma.
对于成年脑低级别胶质瘤患者的治疗策略,目前尚无共识。诊断和初始治疗通常通过手术进行。一些研究者怀疑术后放疗(RT)的疗效,而另一些人则建议常规术后放疗。我们报告了一项关于这一争议的多中心随机试验的初步结果。
从1986年3月至1997年9月,来自24个欧洲中心的311例成年低级别胶质瘤患者在手术后被集中随机分配到试验的两个组。放疗组在6周内接受54 Gy的照射。其他患者在手术后直到肿瘤出现进展(定义为临床神经功能恶化和影像学上肿瘤进展的证据)之前不接受任何治疗。
在290例符合条件且可评估的患者(93%)中,放疗组在进展时间方面有显著改善(对数秩检验p = 0.02),但总生存期无改善,中位随访时间为5年。治疗组和对照组的5年估计值分别为:总生存期63%对66%,进展时间44%对37%。当85例对照组患者出现肿瘤进展时,采用了包括放疗在内的不同治疗方式。
对于低级别胶质瘤患者,如本方案所采用的早期术后常规放疗似乎可改善进展时间或无进展生存期,但不能改善总生存期。